HENRY A. PETERS, M.D.; SHERWYN WOODS; PETER L. EICHMAN, M.D.; HANS H. REESE, M.D., F.A.C.P.
Acute porphyria, especially its therapy, has challenged the clinician for years. The mortality rate when associated with severe neuropsychiatric manifestations is quoted as from 80 to 90%.1 Favorable therapeutic response to 2,3-dimercaptopropanol (BAL)3 and disodium calcium ethylene diamine tetra-acetate (EDTA)4 was reported by Peters2, 3 in seven of 10 cases of acute porphyria, and by McCabe4 in one case of acute porphyria benefited by BAL administration. Paul and Thyresson5 and Schrumpf6 reported the ameliorating effects of BAL in cutaneous porphyria. Dean7 recorded one case not benefited by BAL.
A total of 30 porphyria cases, including our previously reported patients,2, 3
PETERS HA, WOODS S, EICHMAN PL, REESE HH. THE TREATMENT OF ACUTE PORPHYRIA WITH CHELATING AGENTS: A REPORT OF 21 CASES1. Ann Intern Med. ;47:889–899. doi: 10.7326/0003-4819-47-5-889
Download citation file:
Published: Ann Intern Med. 1957;47(5):889-899.
Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use